MIM
PCVX icon

Monashee Investment Management’s Vaxcyte PCVX Stock Holding History

Monashee Investment Management’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-40,000
Closed -$4.57M – 81
2024
Q3 		$4.57M Buy
+40,000
New +$3.6M 0.49% 26
2024
Q2 		– Sell
-100,000
Closed -$6.83M – 119
2024
Q1 		$6.83M Buy
100,000
+62,500
+167% +$4.33M 0.81% 19
2023
Q4 		$2.35M Buy
+37,500
New +$1.95M 0.42% 24
2020
Q3 		– Sell
-80,000
Closed -$2.53M – 233
2020
Q2 		$2.53M Buy
+80,000
New +$2.57M 0.38% 84

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Monashee Investment Management's PCVX Position: Q4 2024 in Review

Monashee Investment Management sold out of Vaxcyte (PCVX) in Q4 2024, closing a stake of 40,000 shares — an estimated $4.57M sold.

Monashee Investment Management first reported a position in PCVX in Q2 2020 and held it in 4 quarters. The position peaked at $6.83M in Q1 2024. 323 funds tracked by Wall St. Rank hold PCVX as of Q4 2024.

  • Monashee Investment Management reported no remaining Vaxcyte position as of Q4 2024 after selling out during the quarter.
  • Monashee Investment Management sold 40,000 Vaxcyte shares in Q4 2024, an estimated $4.57M.
  • Monashee Investment Management first reported a position in Vaxcyte in Q2 2020 and held it in 4 quarters.
  • Monashee Investment Management's Vaxcyte position peaked at $6.83M in Q1 2024.
  • 323 funds tracked by Wall St. Rank held Vaxcyte as of Q4 2024.

Based on Monashee Investment Management's 13F filing for Q4 2024, filed 14 Feb 2025.